Sepsis is a potentially lethal systemic response to infection which remains a critical challenge in emergency medicine. A recent research showed High Mobility Group Box Protein 1 (HMGB1) as a promising biomarker. This protein, ubiquitously expressed in the nucleus, emerges as a significant marker in the early stages of sepsis: this can potentially change how emergency care identifies and manages this condition.
HMGB1 is released into the circulatory system both passively by necrotic cells and actively by inflammatory cells. It is a part of the damage-associated molecular pattern (DAMP) family, playing a crucial role in the innate immune response. When released, HMGB1 binds to cell surface receptors, activating endothelial cells and increasing the production of pro-inflammatory cytokines and chemokines. This process is very important in the early inflammatory response to infections and organ damages.
Recent researches have shown that higher concentrations of HMGB1 are associated with increased mortality in sepsis cases. This correlation has been a focal point in recent studies which aimed to establish a link between prehospital HMGB1 levels and sepsis among nontrauma, nonarrest patients.
The findings show that patients with Sepsis-3 on arrival at the hospital had significantly higher median prehospital HMGB1 levels compared to those without sepsis.
Measuring HMGB1 levels could be instrumental in the early recognition of sepsis, considering that HMGB1 offers a more direct insight into the innate immune response and inflammatory processes. This approach could significantly improve patient outcomes, as early intervention is crucial in managing sepsis.
HMGBiotech can provide comprehensive information to facilitate informed decision-making for research involving HMGB1.
Contact us for your pre-sales questions about HMGB1
Read the full article about the study: